The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000702314p
Ethics application status
Help: Ethics application status
Not yet submitted
Date submitted
Help: Date submitted
13/05/2026
Date registered
Help: Date registered
12/06/2026
Date last updated
Help: Date last updated
12/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
12/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Using patient-specific clinical characteristics and genetic testing to predict the best weight loss medication for adults with obesity
Scientific title
A stratified, randomised controlled trial evaluating phenotype-guided therapy and a genetic risk score (CTSGRS) to predict differential weight loss response to phentermine–topiramate versus GLP-1–based therapy in adults with obesity
Additional trial identifiers [1] 316976 0
Nil
Universal Trial Number (UTN)
U1111-1338-4758
Trial acronym
PREDICT-OBESITY
Related trial records

Health condition
Health condition(s) studied:
Obesity 341438 0
Overweight with metabolic comorbidities 341439 0
Condition category
Condition code
Metabolic and Endocrine 337500 337500 0 0
Metabolic disorders
Diet and Nutrition 337501 337501 0 0
Obesity

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Arm 1:
- Phentermine + Topiramate
- Dose: Phentermine 15 mg orally once daily; Topiramate commencing at a dose of 25mg daily and then up-titrating by 25mg every 2 weeks, if tolerated until a dose of 100mg daily is reached (Week 1 and 2: Phentermine 15 mg mane + Topiramate 25 mg nocte; Week 3 and 4: Phentermine 15 mg mane + Topiramate 50 mg nocte; Week 5 and 6: Phentermine 15 mg mane + Topiramate 25 mg mane and 50 mg nocte; Week 7-30: Phentermine 15 mg mane + Topiramate 50 mg mane and 50 mg nocte). Maintenance dose is maximum tolerated dose or maximum dose defined in the protocol.
- Duration: up to 30 weeks (24weeks on maintenance dose)
- Mode: Phentermine oral capsule; Topiramate oral tablets.
- Adherence: Regular phone follow-ups
Arm 2:
GLP-1 based therapy (Semaglutide or Tirzepatide allocated using randomisation stratified by CTS)
Arm 2, Stratum B:
- Tirzepatide
- Dose: 2.5 mg -> 15 mg weekly. Tirzepatide commencing at a dose of 2.5mg weekly and then up-titrating every 4 weeks, if tolerated until a dose of 15mg weekly is reached (Week 1-4: Tirzepatide 2.5mg weekly; Week 5-8: Tirzepatide 5mg weekly; Week 9-12: Tirzepatide 7.5mg weekly; Week 13-16: Tirzepatide 10mg weekly; Week 17-20: Tirzepatide 12.5mg weekly; Week 21-44: Tirzepatide 15mg weekly). Maintenance dose is maximum tolerated dose or maximum dose defined in the protocol.
- Duration: up to 44 weeks (24eeks on maintenance dose)
- Mode: Subcutaneous injection delivered by pre-filled multi-dose pens
- Adherence: Regular phone follow-ups
Intervention code [1] 333720 0
Diagnosis / Prognosis
Intervention code [2] 333721 0
Treatment: Drugs
Description of the comparator or control
Arm 2, Stratum A:
- Semaglutide
- Dose: 0.25 mg -> 2.4 mg weekly. Semaglutide commencing at a dose of 0.25mg weekly and then up-titrating every 4 weeks, if tolerated until a dose of 2.4mg weekly is reached (Week 1-4: Semaglutide 0.25mg weekly; Week 5-8: Semaglutide 0.5mg weekly; Week 9-12: Semaglutide 1mg weekly; Week 13-16: Semaglutide 1.7mg weekly; Week 17-40: Semaglutide 2.4mg weekly). Maintenance dose is maximum tolerated dose or maximum dose defined in the protocol.
- Duration: up to 40 weeks (24weeks on maintenance dose)
- Mode: Subcutaneous injection delivered by pre-filled multi-dose pens
- Adherence: Regular phone follow-ups
Control group
Active

Outcomes
Primary outcome [1] 345008 0
Percentage total change is body weight.
Timepoint [1] 345008 0
Baseline, at the end of titration phase and 24 weeks after achieving maintenance dose (primary endpoint)
Secondary outcome [1] 460099 0
Proportion achieving >=5% weight change
Timepoint [1] 460099 0
Baseline, at the end of the titration phase, and 24 weeks after achieving maintenance dose (primary endpoint)
Secondary outcome [2] 461973 0
Proportion achieving >=10% weight change
Timepoint [2] 461973 0
Baseline, at the end of the titration phase, and 24 weeks after achieving maintenance dose (primary endpoint)
Secondary outcome [3] 461974 0
Proportion achieving >=15% weight change
Timepoint [3] 461974 0
Baseline, at the end of the titration phase, and 24 weeks after achieving maintenance dose (primary endpoint)
Secondary outcome [4] 461975 0
Proportion of participants with adverse events.
Timepoint [4] 461975 0
At end of titration phase and 24 weeks after achieving maintenance dose (primary endpoint). At unscheduled visits, if adverse events are reported in between scheduled study visits.
Secondary outcome [5] 461976 0
Predictive performance of the calorie-to-satiation genetic risk score (CTSGRS) for weight loss response.
Timepoint [5] 461976 0
At 24 weeks after achieving maintenance dose.
Secondary outcome [6] 461977 0
Availability of properly stored biospecimens for future genomic, epigenomic, proteomic, and metabolomic analyses
Timepoint [6] 461977 0
Baseline and 24weeks after achieving maintenance dose (primary endpoint)
Secondary outcome [7] 461978 0
Change in HbA1c
Timepoint [7] 461978 0
Baseline, end of titration phase, and 24 weeks after achieving maintenance dose (primary endpoint)
Secondary outcome [8] 461979 0
Change in fasting glucose.
Timepoint [8] 461979 0
Baseline, end of titration phase, and 24 weeks after achieving maintenance dose (primary endpoint)
Secondary outcome [9] 461980 0
Change in fasting lipid profile.
Timepoint [9] 461980 0
Baseline, end of titration phase, and 24 weeks after achieving maintenance dose (primary endpoint)
Secondary outcome [10] 461981 0
Change in liver function tests.
Timepoint [10] 461981 0
Baseline, end of titration phase, and 24 weeks after achieving maintenance dose (primary endpoint)
Secondary outcome [11] 461982 0
Change in resting energy expenditure
Timepoint [11] 461982 0
Baseline and 24 weeks after achieving maintenance dose (primary endpoint)
Secondary outcome [12] 461983 0
Change in postprandial energy expenditure
Timepoint [12] 461983 0
Baseline and 24 weeks after achieving maintenance dose (primary endpoint)
Secondary outcome [13] 461984 0
Change in eating behaviour
Timepoint [13] 461984 0
Baseline and 24 weeks after achieving maintenance dose (primary endpoint)
Secondary outcome [14] 461985 0
Change in cravings.
Timepoint [14] 461985 0
Baseline and 24 weeks after achieving maintenance dose (primary endpoint)
Secondary outcome [15] 461986 0
Change in psychological measures
Timepoint [15] 461986 0
Baseline and 24 weeks after achieving maintenance dose (primary endpoint)

Eligibility
Key inclusion criteria
- Patients 18-65 years old with obesity BMI >=30kg/m2 or BMI >=27kg/m2 and at least one obesity-related chronic disease such as type 2 diabetes mellitus, hypertension, obstructive sleep apnoea, amongst others.
- Individuals undergoing an evaluation for weight loss interventions (e.g., diet, medication, bariatric procedures, or weight loss surgery).
- Ability and willingness to comply with the study protocol including completion of all procedures, study visits, questionnaires, assessments for the duration of the study.
- Ability and willingness to self-administer the injectables.
- Agreement to adhere to the contraception requirements.
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
- No indication for weight loss medications
- Already on weight loss medications or within 3months of enrolment into the study.
- History of chronic gastrointestinal diseases
- Prior weight loss surgery and/or GI surgery
- Pregnancy or women planning pregnancy
- Uncontrolled systemic disease/mental health illness
- Uncontrolled hypertension
- Medications that can affect GI motility and appetite
- H/O acute or chronic pancreatitis or clinically significant gall bladder diseases.
- Known personal or family H/O MEN-2 syndrome or medullary thyroid cancer.
- Hypersensitivity to any of the study medications
- Food intolerances to the meals involved in the study

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Centralised computer-generated randomisation will be implemented through the REDCap randomisation module. The allocation sequence will be concealed from investigators and recruiting clinicians until the participant has been enrolled and assigned to an intervention group.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
The randomisation sequence will be computer-generated using permuted block randomisation with variable block sizes of 2, 4, and 6, generated using the BlockRand package in R. Participants will be stratified according to clinical calorie-to-satiation (CTS) group prior to randomisation.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
The primary analysis will evaluate whether the effect of treatment on TBWL differs according to CTS and CTSGRS groups. This will be assessed using a 2 × 2 factorial analysis of variance (ANOVA), with CTS and CTSGRS groups (high vs low) and treatment assignment (phentermine–topiramate vs GLP-1–based therapy) as fixed factors, including an interaction term.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD

Funding & Sponsors
Funding source category [1] 321574 0
Hospital
Name [1] 321574 0
Logan Endocrine and Diabetes Services
Country [1] 321574 0
Australia
Primary sponsor type
Government body
Name
MetroSouth Health, Queensland Health
Address
Country
Australia
Secondary sponsor category [1] 324369 0
None
Name [1] 324369 0
Address [1] 324369 0
Country [1] 324369 0
Other collaborator category [1] 283897 0
University
Name [1] 283897 0
Centre for Genomics and Personalised Health, Queensland University of Technology
Address [1] 283897 0
Country [1] 283897 0
Australia
Other collaborator category [2] 283898 0
Hospital
Name [2] 283898 0
Precision Medicine for Obesity program, Mayo clinic, Rochester, Minnesota, USA
Address [2] 283898 0
Country [2] 283898 0
United States of America

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 320105 0
Metro South Human Research Ethics Committee
Ethics committee address [1] 320105 0
Ethics committee country [1] 320105 0
Australia
Date submitted for ethics approval [1] 320105 0
18/06/2026
Approval date [1] 320105 0
Ethics approval number [1] 320105 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149446 0
Dr Kanakamani Jeyaraman
Address 149446 0
Logan Endocrine and Diabetes services, Logan Hospital, Cnr Armstrong and Loganlea Road, Meadowbrook, QLD-4131
Country 149446 0
Australia
Phone 149446 0
+61 07 2891 4232
Fax 149446 0
Email 149446 0
Contact person for public queries
Name 149447 0
Kanakamani Jeyaraman
Address 149447 0
Logan Endocrine and Diabetes services, Logan Hospital, Cnr Armstrong and Loganlea Road, Meadowbrook, QLD-4131
Country 149447 0
Australia
Phone 149447 0
+61 07 2891 4232
Fax 149447 0
Email 149447 0
Contact person for scientific queries
Name 149448 0
Kanakamani Jeyaraman
Address 149448 0
Logan Endocrine and Diabetes services, Logan Hospital, Cnr Armstrong and Loganlea Road, Meadowbrook, QLD-4131
Country 149448 0
Australia
Phone 149448 0
+61 07 2891 4232
Fax 149448 0
Email 149448 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• De-identified individual participant data:
• Published results
What types of analyses could be done with individual participant data?
• Systematic reviews and meta-analyses
• Studies exploring new research questions
• Health economic analyses
• Studies testing whether findings can be repeated or confirmed
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
A finite period of: 5 years
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
Yes: To comply with institutional data sharing policies



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.